TriangleTestosterone cypionate (NCT04363164)
Testosterone cypionate trial for Castration Resistant Metastatic Prostate Cancer (NCT04363164). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for men aged eighteen to ninety with metastatic castration-resistant prostate cancer progressing on abiraterone plus androgen deprivation, without cancer pain requiring medication. Previous enzalutamide, apalutamide, darolutamide, or chemotherapy for castration-resistant disease excludes participation.
The idea: testosterone injections raise hormone levels; enzalutamide blocks androgen signaling. Randomization assigns continuous enzalutamide, eight-week alternation with testosterone, or switching guided by PSA progression. Androgen deprivation continues. Researchers compare clinical or imaging progression; biopsies are required when feasible.
This phase 2 study plans 150 patients. Samuel Denmeade leads at Johns Hopkins, Baltimore; six US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.